Related Experiment Videos
Moxalactam therapy of difficult infections in patients with serious underlying conditions
Abstract:
Moxalactam was the single therapeutic agent used to treat a variety of infections in sixty-three patients, most of whom had serious concomitant illnesses. Fifty-three patient case reports qualified for evaluation, including those with pneumonia (8), urinary tract infections (18), superficial infections (6), orthopaedic infections (7), osteomyelitis (8), septicaemia (4), pansinusitis (1), and meningitis (1). Preliminary in vitro studies had indicated that most organisms, including those resistant to other antibacterial agents, would respond to moxalactam. Infecting bacteria from the fifty-three evaluable patients included a wide variety of Gram-positive and Gram-negative organisms. Doses of moxalactam ranged from 1 to 16 g/day administered intravenously or intramuscularly for 5 to 41 days. With few explainable exceptions, clinical and bacteriologic responses were adequate and satisfactory. Adverse effects were inconsequential. Allergic reactions were not observed, even in patients with a past history of reactions to penicillin.
Insights
Moxalactam effectively treated diverse infections in 53 patients, including serious conditions. This antibiotic showed satisfactory clinical and bacteriologic responses with minimal adverse effects, even in penicillin-allergic individuals.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Moxalactam demonstrated promising in vitro activity against various pathogens, including those resistant to other antibiotics.
- Patients often presented with serious comorbidities, necessitating effective therapeutic options.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of moxalactam as a single therapeutic agent.
- To assess moxalactam's effectiveness across a spectrum of bacterial infections.
Main Methods:
- A cohort of 63 patients with various infections received moxalactam as the sole treatment.
- Fifty-three patient case reports were evaluated, encompassing infections such as pneumonia, urinary tract infections, osteomyelitis, and septicaemia.
- Moxalactam was administered intravenously or intramuscularly at doses ranging from 1 to 16 g/day for 5 to 41 days.
Main Results:
- Moxalactam achieved adequate and satisfactory clinical and bacteriologic responses in most evaluable patients.
- The spectrum of treated infections included Gram-positive and Gram-negative organisms.
- Adverse effects were minimal and inconsequential, with no observed allergic reactions, even in patients with prior penicillin allergy.
Conclusions:
- Moxalactam is a safe and effective antibiotic for treating a wide range of bacterial infections.
- Its favorable safety profile, particularly in patients with penicillin sensitivity, makes it a valuable therapeutic option.